Irisin in elderly people with hypertension, diabetes mellitus type 2, and overweight and obesity
- 3 Downloads
This study aimed to investigate the irisin levels in elderly patients with hypertension, diabetes mellitus type 2, and overweight and obesity, to investigate the possible association between irisin levels and anthropometric and biochemical parameters, and also to assess the irisin levels associated with a risk of hypertension, diabetes mellitus type 2, and overweight and obesity.
A nested case-control study was conducted, with hypertension, diabetes mellitus type 2, and overweight and obesity being set as the case group; 71 elderly patients from the cohort were enrolled in each case group, and 71 healthy elderly from the cohort were included in the control group. The anthropometric and biochemical parameters were measured in all elderly, and irisin levels were measured using enzyme-linked immunosorbent assay.
The irisin levels were significantly lower in patients with hypertension, diabetes mellitus type 2, and overweight and obesity than in controls (p < 0.001). Irisin levels were negatively correlated with body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, cholesterol, triglyceride, and alanine aminotransferase. Moreover, the model adjusted for body mass index, systolic blood pressure, diastolic blood pressure, and fasting blood glucose showed that increasing irisin levels were associated with a reduced risk of hypertension, diabetes mellitus type 2, and overweight and obesity. Receiver operating characteristic curve analysis showed that the area under the curve was 0.779 for hypertension, 0.976 for diabetes mellitus type 2, and 0.957 for overweight and obesity.
Irisin may thus play a role in blood pressure and blood glucose regulation.
KeywordsIrisin T2DM Hypertension Overweight and obesity Cardiovascular
We are grateful to all the study subjects for their participants.
This work was supported by the Fujian Science and Technology Project Induction Project (2018D0009) and the undergraduate program of basic innovation research fund of Xiamen University (2017X0050, 2017Y0077).
Compliance with ethical standards
The study were approved by the ethics committee of School of Public health, Xiamen University. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.
The authors declare that they have no conflict of interest.
Informed consent was obtained from all individual participants included in the study.
- 1.National Health and Family Planning Commission of the People’s Republic of China, The fifth national health services survey analysis report, 2016, www.nhfpc.gov.cn. Acessed 20 Oct 2017
- 2.Chen W, Gao R, Liu L, et al. Cardiovascular disease report in China. Chin Circ J. 2017;1(33):1–8.Google Scholar
- 3.Yang F, Qian D, Hu D, et al. Prevalence of cardiovascular disease risk factor clustering in Chinese adults. Clin Trial Regul Sci Cardiol. 2016;3(15)):1–6.Google Scholar
- 13.Fu J, Han Y, Wang J, et al. Irisin lowers blood pressure by improvement of endothelial dysfunction via AMPK-Akt-eNOS-NO pathway is the spontaneously hypertensive rat. Am Heart Assoc. 2016;5(11):e003433.Google Scholar
- 17.Zhang Y, Sun Y, Ding S-Z. The novel myokine-irisin. Chin J Biochem Mol Biol. 2017;33(5):429–35.Google Scholar